| Item Type | Name |
|
Concept
|
Adenocarcinoma
|
|
Concept
|
Age Factors
|
|
Concept
|
Breast
|
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Antimetabolites, Antineoplastic
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Carcinoma, Renal Cell
|
|
Concept
|
Biopsy
|
|
Concept
|
Carcinoma, Non-Small-Cell Lung
|
|
Concept
|
Chicago
|
|
Concept
|
Cisplatin
|
|
Concept
|
Clinical Competence
|
|
Concept
|
Contrast Media
|
|
Concept
|
Diet
|
|
Concept
|
Cyclophosphamide
|
|
Concept
|
Oncogenes
|
|
Concept
|
Patient Care Planning
|
|
Concept
|
Receptors, Estrogen
|
|
Concept
|
Intensive Care Units
|
|
Concept
|
Prednisone
|
|
Concept
|
Prostatic Neoplasms
|
|
Concept
|
Risk Factors
|
|
Concept
|
Interprofessional Relations
|
|
Concept
|
Cohort Studies
|
|
Concept
|
Incidence
|
|
Concept
|
Training Support
|
|
Concept
|
Dinoprostone
|
|
Concept
|
Randomized Controlled Trials as Topic
|
|
Concept
|
Vegetables
|
|
Concept
|
Paclitaxel
|
|
Concept
|
Prostate-Specific Antigen
|
|
Concept
|
Postmenopause
|
|
Concept
|
Patient-Centered Care
|
|
Concept
|
Disease Progression
|
|
Concept
|
Angiogenesis Inhibitors
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Concept
|
Methylenetetrahydrofolate Reductase (NADPH2)
|
|
Concept
|
Carcinoma, Small Cell
|
|
Concept
|
Area Under Curve
|
|
Concept
|
Mucositis
|
|
Concept
|
Receptors, Progesterone
|
|
Concept
|
Schools, Medical
|
|
Concept
|
Testosterone
|
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Survival Rate
|
|
Concept
|
Receptor, ErbB-2
|
|
Concept
|
Ki-67 Antigen
|
|
Concept
|
Gadolinium DTPA
|
|
Concept
|
Transcriptome
|
|
Concept
|
Pandemics
|
|
Concept
|
Intention to Treat Analysis
|
|
Concept
|
Clinical Trials as Topic
|
|
Concept
|
Deoxycytidine
|
|
Concept
|
Drug Eruptions
|
|
Concept
|
Doxorubicin
|
|
Concept
|
Follow-Up Studies
|
|
Concept
|
Prospective Studies
|
|
Concept
|
Retrospective Studies
|
|
Academic Article
|
Novel therapies in lung cancer.
|
|
Academic Article
|
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
|
|
Academic Article
|
Sorafenib.
|
|
Academic Article
|
Non-receptor tyrosine kinase inhibitors in lung cancer.
|
|
Academic Article
|
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
|
|
Academic Article
|
Phase II trial of temsirolimus in patients with metastatic breast cancer.
|
|
Academic Article
|
Randomized controlled trials and comparative effectiveness research.
|
|
Academic Article
|
Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma.
|
|
Academic Article
|
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
|
|
Academic Article
|
Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting?
|
|
Academic Article
|
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).
|
|
Academic Article
|
Medical Student Knowledge of Oncology and Related Disciplines: a Targeted Needs Assessment.
|
|
Academic Article
|
No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations.
|
|
Academic Article
|
Interdisciplinary Oncology Education: a National Survey of Trainees and Program Directors in the United States.
|
|
Academic Article
|
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
|
|
Academic Article
|
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
|
|
Academic Article
|
Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer.
|
|
Academic Article
|
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
|
|
Academic Article
|
Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance).
|
|
Academic Article
|
Implementation of a Novel Medical School Multidisciplinary and Interprofessional Oncology Curriculum: a Mixed Method Study.
|
|
Academic Article
|
PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer.
|
|
Academic Article
|
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].
|
|
Academic Article
|
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
|
|
Academic Article
|
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.
|
|
Academic Article
|
Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).
|
|
Academic Article
|
Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design.
|
|
Academic Article
|
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
|
|
Academic Article
|
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
|
|
Academic Article
|
Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.
|
|
Academic Article
|
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
|
|
Academic Article
|
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
|
|
Academic Article
|
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
|
|
Academic Article
|
Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance).
|
|
Academic Article
|
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
|
|
Academic Article
|
Goals of care discussions: perceptions of radiation and medical oncologists.
|
|
Academic Article
|
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
|
|
Academic Article
|
Impact of the COVID-19 Pandemic on Cancer Clinical Trials.
|
|
Academic Article
|
Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.
|
|
Academic Article
|
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
|
|
Academic Article
|
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
|
|
Academic Article
|
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
|
|
Academic Article
|
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
|
|
Academic Article
|
Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]).
|
|
Academic Article
|
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.
|
|
Concept
|
Celecoxib
|
|
Concept
|
Bevacizumab
|
|
Concept
|
Trastuzumab
|
|
Concept
|
Capecitabine
|
|
Concept
|
Abiraterone Acetate
|
|
Concept
|
Ipilimumab
|
|
Concept
|
Prostatic Neoplasms, Castration-Resistant
|
|
Concept
|
ErbB Receptors
|
|
Academic Article
|
The Impact of Race and Age on Response to Neoadjuvant Therapy and Long-Term Outcomes in Black and White Women with Early-Stage Breast Cancer.
|
|
Academic Article
|
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
|
|
Academic Article
|
Adapting a Medical School Cancer Research Education Program to the Virtual Environment: a Mixed-Methods Study.
|
|
Academic Article
|
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer.
|
|
Academic Article
|
Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance).
|
|
Academic Article
|
Validation of the RSClin risk calculator in the National Cancer Data Base.
|
|
Academic Article
|
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
|